Martin Lee to Diabetes Mellitus, Type 2
This is a "connection" page, showing publications Martin Lee has written about Diabetes Mellitus, Type 2.
Connection Strength
0.940
-
Davidson MB, Duran P, Lee ML. Community screening for pre-diabetes and diabetes using HbA1c levels in high-risk African Americans and Latinos. Ethn Dis. 2014; 24(2):195-9.
Score: 0.288
-
Frias JP, Lee ML, Carter MM, Ebel ER, Lai RH, Rikse L, Washington ME, Sonnenburg JL, Damman CJ. A microbiome-targeting fibre-enriched nutritional formula is well tolerated and improves quality of life and haemoglobin A1c in type 2 diabetes: A double-blind, randomized, placebo-controlled trial. Diabetes Obes Metab. 2023 05; 25(5):1203-1212.
Score: 0.135
-
Rosenson RS, Lee ML, Chen Q. Association of total VLDL particle concentrations with elevated blood viscosity in patients with type 2 diabetes. Diabetes Res Clin Pract. 2022 Jan; 183:109180.
Score: 0.125
-
Hsia SH, Duran P, Lee ML, Davidson MB. Randomized controlled trial comparing hydroxychloroquine with pioglitazone as third-line agents in type 2 diabetic patients failing metformin plus a sulfonylurea: A pilot study. J Diabetes. 2020 Jan; 12(1):91-94.
Score: 0.108
-
Rosenson RS, Chen Q, Najera SD, Krishnan P, Lee ML, Cho DJ. Ticagrelor improves blood viscosity-dependent microcirculatory flow in patients with lower extremity arterial disease: the Hema-kinesis clinical trial. Cardiovasc Diabetol. 2019 06 07; 18(1):77.
Score: 0.105
-
Rosenson RS, Chen Q, Najera SD, Lee ML, Cho DJ. Ticagrelor and the Prevention of Microvascular Complications in Diabetes Patients with Lower Extremity Arterial Disease; Rationale and Design of the Hema-Kinesis Trial. Cardiovasc Drugs Ther. 2018 10; 32(5):443-451.
Score: 0.100
-
Mojtahedzadeh M, Lee ML, Friedman TC. Continuation or discontinuation of pioglitazone when starting bedtime insulin in patients with poorly controlled type 2 diabetes in an inner-city population. J Diabetes Complications. 2015 Nov-Dec; 29(8):1248-52.
Score: 0.080